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and found that the virus replicates to high titer, sheds apically, targets ciliated cells, and induces min-
imal cytopathology. Replication of an experimental, live attenuated HPIV2 vaccine strain, containing
both temperature sensitive (ts) and non-ts attenuating mutations, was restricted >30-fold compared to
rHPIV2-WT in HAE at 32 ◦C and exhibited little productive replication at 37 ◦C. This restriction paralleled
attenuation in the upper and lower respiratory tract of African green monkeys, supporting the HAE model
as an appropriate and convenient system for characterizing HPIV2 vaccine candidates.ive attenuated vaccine candidate
uman ciliated airway epithelium
. Introduction
Human parainfluenza virus type 2 (HPIV2) is an enveloped,
ingle-stranded, non-segmented, negative-sense RNA virus of the
ubulavirus genus in the Paramyxoviridae family [1]. Similar to res-
iratory syncytial virus (RSV), influenza virus, HPIV1 and HPIV3,
PIV2 is an important cause of severe lower respiratory tract dis-
ase, including croup, bronchiolitis and pneumonia, in children
ess than 6 years old. HPIVs account for up to 18% of all pediatric
ospitalizations for respiratory tract diseases, with HPIV2 alone
stimated to be responsible for approximately 3% [2,3]. In addi-
ion, HPIV2 causes significant morbidity in infants and children that
equires medical attention but not hospitalization [2,4]. Licensed
accines are currently not available for any HPIV, despite their sig-
ificant impact on public health.
Our goal is to develop a cDNA derived, live attenuated HPIV2
accine that is safe, genetically stable, and protective against lower
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respiratory tract disease in young children. The live attenuated
vaccine strategy offers several advantages over inactivated or sub-
unit formulations, including the ability to elicit broadly protective
immune responses consisting of local and serum antibodies as well
as CD4+ and CD8+ T cell responses [5]. Furthermore, live attenu-
ated vaccines administered intranasally replicate in the respiratory
tract in the presence of maternal antibody, permitting immuniza-
tion of young infants, and cause an acute, self-limited infection
that is readily eliminated from the respiratory tract [5,6]. Finally,
intranasal administration of live attenuated virus vaccines induces
mucosal antigen-specific immune responses in the upper respira-
tory tract (URT), which have a major impact on limiting replication
of respiratory viruses in the airways [7,8]. Several cDNA derived,
intranasally administered live attenuated virus vaccines have been
evaluated in clinical trials and were found to be safe and immuno-
genic, including the licensed influenza virus vaccine (FluMist®)
and investigational vaccines against HPIV3 (rHPIV3cp45) and RSV
(rA2cp248/404/1030SH) [6,9–13].
The development of in vitro and in vivo tests to identify live
attenuated respiratory virus vaccine candidates that will exhibit a
satisfactory balance between attenuation and immunogenicity in
humans is needed. Extensive in vivo studies are often performed
during preclinical vaccine development since cell lines generally
do not accurately reveal the level of attenuation of viral vaccine
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estricted host range of human paramyxoviruses requires the use
f non-human primates, a limited and expensive resource, to assess
he level of attenuation. Therefore, the availability of an in vitro tis-
ue culture model system that reflects the restriction of replication
f attenuated human respiratory viruses in non-human primates
nd ultimately humans would be desirable for preclinical devel-
pment of such live attenuated virus vaccines. Using an in vitro
ystem, the level of attenuation of multiple vaccine candidates
ould be rapidly assessed and suitable vaccine candidates could
e selected for further evaluation in non-human primates and in
umans.
HPIVs and RSV replicate primarily, if not exclusively, in epithe-
ial cells of the respiratory tract unless the individual is severely
mmunocompromised [14–17]. In vitro models of human ciliated
irway epithelium (HAE) derived from freshly isolated human air-
ay cells and grown at an air–liquid interface have been shown
o closely mimic the morphological and physiological characteris-
ics of the human airway epithelium in vivo, including mucociliary
ransport [18,19]. Furthermore, such HAE models have been used to
nvestigate characteristics of viral infection for a number of respi-
atory viruses, including human coronaviruses, influenza A viruses,
SV, HPIV1 and HPIV3 [20–25]. Although each of these viruses
nfects ciliated cells in this model, the consequences of infection
ary. For example, infection by influenza A viruses causes exten-
ive early cytopathology in HAE [24,26], whereas RSV, HPIV1 and
PIV3 do not cause overt early cytopathology [20–22]. The ciliated
ell tropism of these viruses and the critical role of ciliated cells
n innate airway defense suggest a central role for ciliated cells in
irus replication and spread with likely adverse consequences for
he function of the epithelium of the respiratory tract [20–22].
We propose that HAE culture models may be used to assess
estriction of replication in vitro that will parallel restricted replica-
ion and attenuation of illness in the human host. We have chosen
o test the utility of HAE to estimate the level of attenuation of a
ive attenuated cDNA derived HPIV2 vaccine candidate designated
ere as rHPIV2-VAC. This vaccine candidate has been administered
o the upper and lower respiratory tract of African green mon-
eys (AGMs) and is currently in phase 1 clinical trials. rHPIV2-VAC
as designed to contain three attenuating elements: a T to C sub-
titution at nucleotide 15 in the 3′ genomic promoter (15T–C); a
ubstitution in the viral polymerase (LY948L); and a deletion in the
olymerase (Ldel1724) [27–29]. The 15T–C mutation was originally
dentified as a spontaneous mutation following in vitro passage
f wild-type (WT) HPIV2 in LLC-MK2 cells. This mutation is non-
emperature sensitive (non-ts) and efficiently attenuates the virus
n both the upper (URT) and lower (LRT) respiratory tract of AGMs
s well as in the LRT of hamsters [29]. The LY948L mutation was orig-
nally identified as a ts attenuating mutation in the L polymerase of
he HPIV3cp45 vaccine candidate [30]. The stability of the mutant
PIV2 LY948L sequence was enhanced by genetically engineering a
odon assignment that would require three nucleotide changes to
evert to the original, wild-type tyrosine amino acid assignment
27]. This substitution mutation in HPIV2 resulted in ts and att
henotypes with restriction of replication observed in the LRT of
GMs and hamsters [27,29]. Lastly, deletion of codons 1724 and
725 in L of HPIV2 (Ldel1724) increased the level of temperature
ensitivity and attenuation of rHPIV2 bearing the 15T–C and LY948L
utations and should confer a more stable attenuation phenotype
han the point mutation from which it was derived (a LS1724I att
oint mutation in bovine PIV3) [27,30]. The rHPIV2-VAC vaccine
andidate virus, containing the above mutations, was found to be
s in vitro, with a replication shut-off temperature of 37 ◦C, and
anifested restricted replication in the URT and LRT of AGMs [29].
he mean peak titer of rHPIV2-VAC was reduced 60-fold in the URT
nd 4000-fold in the LRT of infected AGMs compared to that of
HPIV2-WT [29]. rHPIV2-VAC induced a moderate rise in HPIV228 (2010) 2788–2798 2789
hemagglutination-inhibiting (HAI) antibodies in AGMs and immu-
nization protected AGMs against wild-type HPIV2 challenge in both
the UTR and LRT [29].
In the present study, we utilized HAE cultures to first character-
ize rHPIV2-WT infection of the human ciliated airway epithelium
with respect to level and duration of replication, cell tropism, polar-
ity of infection, cytopathology, and cellular response to infection.
Our data demonstrate that HPIV2 infects ciliated cells only, that
virus is released from the apical surface only, and that productive
replication takes place in the absence of early gross morphologi-
cal changes to the epithelium. Efficient replication of rHPIV2-WT
in HAE allowed us to compare the level of restriction of replica-
tion of rHPIV2-VAC in HAE to that previously observed in AGMs.
The restriction of replication of rHPIV2-VAC versus rHPIV2-WT in
HAE at 32 and 37 ◦C correlated closely with that seen in the URT
and LRT, respectively, of AGMs. Ongoing clinical trials will provide
the vaccine virus replication data in seronegative children that is
needed to assess the utility of the HAE system in identifying live
HPIV2 vaccine viruses that are appropriately attenuated.
2. Materials and methods
2.1. Cells and viruses
Human airway tracheobronchial epithelial cells were isolated
from airway specimens of patients without underlying lung dis-
ease. Tissues were provided by the National Disease Research
Interchange (NDRI, Philadelphia, PA) or by the UNC Cystic Fibro-
sis Center Tissue Culture Core as excess tissue following lung
transplantation according to protocols approved by the Institu-
tional Review Board of the University of North Carolina at Chapel
Hill. Primary cells derived from single patient sources were first
expanded on plastic and then plated on collagen-coated, per-
meable Transwell-COL (12-mm diameter) supports at a density
of 3 × 105 cells per well. HAE cultures were grown in custom
media with provision of an air-liquid interface (ALI) for 4–6 weeks
to form differentiated, polarized cultures that resemble in vivo
pseudostratified mucociliary epithelium, as previously described
[19]. Rhesus monkey LLC-MK2 cells (ATCC CCL 7.1) and human
HEp-2 cells (ATCC CCL 23) were maintained in OptiMEM I (Gibco-
Invitrogen, Inc., Grand Island, NY) supplemented with 5% FBS and
gentamicin sulfate (50 g/ml).
The HPIV2 recombinants described here are based on the biolog-
ically derived HPIV2 strain V9412-6 (V94), which was isolated from
a nasal wash specimen from an infected infant and was kindly pro-
vided by Dr. Peter Wright of Vanderbilt University. The sequence
for the V94 strain was determined previously (Genbank accession
#AF533010). The rHPIV2-WT virus was derived from an antige-
nomic cDNA copy of the HPIV2 V94 genome [4]; the genome of
the rHPIV2-VAC vaccine virus is engineered from rHPIV2-WT, as
described previously [27–29]. rHPIV2-VAC, which was referred to
in our previous publication as rHPIV2-15C/948L/1724 [29], con-
tains three attenuating elements: a mutation at nucleotide 15,
15T–C, in the 3′ genomic promoter; a substitution in L, LY948L; and
a six nucleotide deletion in L, Ldel1724. rHPIV1-WT was derived
from HPIV1 strain Washington/20993/1964 [31,32]. Media used for
HPIV1 propagation in LLC-MK2 cells contained 1.2% TrypLE Select, a
recombinant trypsin-like protease (Gibco-Invitrogen, Inc.), to acti-
vate the HPIV1 F protein.
Purified virus stocks were obtained by infecting LLC-MK2 cells
and purifying virus in the cell culture supernatant by centrifuga-
tion and banding in discontinuous 30/60% (w/v) sucrose gradients
in order to minimize contamination by cellular factors. Virus titers
were determined by 10-fold serial dilution on LLC-MK2 cells in
96-well plates. After 7 days at 32 ◦C and 5% CO2, infection was
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iral titers are expressed as 50% tissue culture infectious dose per
l (log10TCID50/ml).
.2. Viral inoculation of HAE
The apical surfaces of HAE cultures were washed with
hosphate-buffered saline (PBS) to limit the effects of apical secre-
ions on inocula, and fresh media was supplied to the basolateral
ompartments prior to inoculation. HPIV viruses diluted in culture
edium were applied to either the apical or basolateral surface of
AE at a MOI of 5.0 TCID50/cell or 1.0 TCID50/cell in a 200 l inocu-
um. After incubation for 2 h at either 32 or 37 ◦C, the inoculum
as removed, and cells were washed three times for 5 min each
ith PBS and then incubated at 32 or 37 ◦C. Virus released into the
pical compartment was harvested by performing apical washes
ith 425 l of media for 30 min at 32 or 37 ◦C. Basolateral sam-
les were collected directly from the basolateral compartment and
he removed volume replaced with fresh media. Samples were col-
ected at 0, 8, 24, 48, 72, 96, and 144 h post-inoculation and stored
t −80 ◦C until analysis.
.3. Kinetics of rHPIV2 replication in LLC-MK2 cells
Confluent monolayer cultures of LLC-MK2 cells in 6-well plates
ere infected in triplicate at a MOI of 5.0 TCID50/cell. After incu-
ation for 1 h with virus, cultures were washed three times and
ncubated at 32 or 37 ◦C, as indicated. Medium from each well was
arvested and replaced with fresh medium at 24 h intervals and
tored at −80 ◦C until analysis. Virus present in each sample was
uantified by titration on LLC-MK2 cells and detected by hemad-
orption.
.4. En face staining and fluorescence microscopy
HAE were fixed overnight at 4 ◦C in methanol:acetone (50/50)
nd then permeabilized with 2.5% Triton X-100. The fixed cells were
locked with 3% bovine serum albumin (BSA) in PBS++ (contain-
ng 1 mM CaCl2 and 1 mM MgCl2) prior to incubating the apical
urfaces with antibodies diluted in 1% BSA. HPIV2-positive cells
ere detected using anti-HPIV2 antibodies obtained from fluid
resent in subcutaneous chambers of rabbits immunized with
urified rHPIV2-WT (1:100 dilution, neutralizing antibody titer
f 1:7000), as described previously [34], followed by addition
f fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit
gG (1:500 dilution; Jackson ImmunoResearch Laboratories, Inc.,
est Grove, PA). HPIV1-positive cells were detected using rabbit
nti-HPIV1 antibody, as described previously [20]. Images were
cquired using a Leica DMIRD inverted fluorescence microscope
quipped with a cooled color charge-coupled device digital camera
MicroPublisher; Q-Imaging, Burnaby, British Columbia, Canada).
he percentage of the epithelium positive for viral antigen as
n index of percentage of infected cells was quantified over 5
mages per culture by black and white pixilation of each image
nd computer calculation of percent black pixels after inverting
he image. This technique determines percentage of black pixels in
defined area and does not account for differences in fluorescent
ntensity.
.5. Histology and immunostainingHAE fixed in methanol:acetone were embedded in paraffin and
repared as 5 m histological sections. Sections were stained with
ematoxylin and eosin (H&E) or Alcian blue-PAS for analysis by
ight microscopy or were subjected to standard immunofluores-
ence protocols. For immunofluorescence, sections were blocked28 (2010) 2788–2798
with 3% BSA in PBS++ and then incubated with primary antibod-
ies, rabbit anti-HPIV2 antibodies (1:100) and mouse anti-acetylated
alpha tubulin (1:2000; Zymed, San Francisco, CA), diluted in 1% BSA.
Primary antibodies were detected with FITC-conjugated goat anti-
rabbit IgG and Rhodamine Red-conjugated goat anti-mouse IgG2b
(Jackson ImmunoResearch Laboratories, Inc.) diluted 1:500. After
washing, cells were overlaid with FluorSave mounting medium
(EMD Chemicals, Inc.).
2.6. Type I IFN bioassay
The amount of type I IFN produced in response to viral infec-
tion of HAE was determined by a previously described IFN bioassay
method [20,35]. Briefly, apical wash samples were pH 2.0-treated
to inactivate virus and acid-labile type II IFN, then serially diluted 2-
fold on HEp-2 cells alongside a human IFN- standard (5000 pg/ml;
Avonex; Biogen, Inc., Cambridge, MA). After 24 h, cells were infected
with recombinant vesicular stomatitis virus (VSV-GFP), obtained
from John Hiscott [36]. GFP expression was measured using a
Typhoon 8600 scanner (Molecular Dynamics Inc., Sunnyvale, CA).
The dilution at which the number of GFP-positive cells approxi-
mated 50% of that for untreated wells was considered the end point
and compared to the end point of the IFN- standard to calculate
the concentration of type I IFN in each sample.
2.7. Adenylate kinase cytotoxicity assay
Cellular toxicity due to HPIV2 infection was determined by mea-
suring the amount of adenylate kinase (AK) leakage into the apical
compartment of HAE. AK is an intracellular enzyme released from
cells only when cell membranes are disrupted and has previously
been shown to correlate with the proportion of dead or damaged
cells after virus infection [37]. To measure cytotoxicity in HPIV2-
infected HAE, aliquots of the apical wash samples collected at
each time point were centrifuged immediately after collection to
eliminate cell debris prior to freezing the sample supernatant. AK
concentrations were determined in the apical wash supernatant
samples using the ToxiLight BioAssay kit (Lonza Rockland, Inc.,
Rockland, ME) according to the manufacturer’s directions. AK activ-
ity upon reaction with the ToxiLight reagent was detected using a
luminescence microplate reader and SoftMax Pro software (Molec-
ular Devices, Sunnyvale, CA).
2.8. Replication of rHPIV2 mutants in the respiratory tract of
AGMs
Studies in HPIV2 seronegative African green monkeys (AGMs)
were previously reported for 11 AGMs infected with rHPIV2-WT
and 4 AGMs infected with rHPIV2-VAC [29]. This historical data
was combined with data from additional AGM studies to yield
larger groups and more accurate comparisons (n = 21 for rHPIV2-
WT, n = 16 for rHPIV2-VAC). The AGMs were inoculated intranasally
and intratracheally with 106.0 TCID50 of recombinant HPIV2 at each
site and nasopharyngeal swabs and tracheal lavage samples were
collected for up to 10 days as described previously [29]. The virus
titer in each sample was determined by serial dilution on LLC-MK2
monolayers at 32 ◦C as described above. The lower limit of detection
was 0.5 log10TCID50/ml.
3. Results3.1. Characterization of HPIV2 infection in primary cultures of
human ciliated airway epithelium
Wild-type HPIV2 (rHPIV2-WT) infection in an in vitro model of
the human ciliated airway epithelium (HAE) was first character-
A. Schaap-Nutt et al. / Vaccine 28 (2010) 2788–2798 2791
Fig. 1. rHPIV2-WT infects HAE and progeny virus is shed from the apical surface. HAE were inoculated via the apical surface with rHPIV2-WT at high MOI (5.0 TCID50/cell).















ultures from 2 donors (3 cultures per donor) ± S.E. The limit of detection is 1.2 lo
ost-inoculation (pi) and immunoprobed en face for the presence of HPIV2 antigen
he percentage of HPIV2-positive cells in HAE (FITC-positive surface area) per cultu
zed. HAE were inoculated at the apical surface with rHPIV2-WT
t high MOI (5.0 TCID50/cell), and apical and basolateral com-
artments were assessed for progeny virus release over time.
uantification of virus in the apical compartment provided evi-
ence of rapid and robust replication and apical shedding of
rogeny rHPIV2-WT in HAE. Titers of rHPIV2-WT increased 100-
old within the first 24 h following apical inoculation and reached a
eak titer of approximately 106 TCID50/ml in the apical wash sam-
les by day 2 post-inoculation (pi) (Fig. 1A), indicating rHPIV2-WT
as able to productively infect HAE. In contrast to the high levels
f virus detected in the apical wash, little or no virus was measuredD50/ml. (B) Representative photomicrographs of HAE fixed at the indicated times
n) after apical inoculation by HPIV2 or vehicle alone (Mock). (C) Quantification of
r time after apical inoculation with rHPIV2-WT. Mean across 10 fields ± S.E..
above the limit of detection in the basolateral compartment at any
time point (Fig. 1A).
The growth kinetics of HPIV2 measured as virus release into
the apical compartment correlated well with the number of cells
staining positive for viral antigen by en face immunostaining for
HPIV2 antigen (Fig. 1B and C). By day 1 pi, viral antigen was
detected in cells dispersed across the surface of HAE. However,
despite high MOI inoculation, on average, only 8–10% of the sur-
face epithelial cells were positive for viral antigen, indicating that
only a minority of HAE cells were infected by the initial inocu-
lum. Since rHPIV2-WT appears to infect primarily ciliated cells
2792 A. Schaap-Nutt et al. / Vaccine 28 (2010) 2788–2798
Fig. 2. rHPIV2-WT, but not rHPIV1-WT, infects HAE via the basolateral surface. (A) HAE was inoculated via the apical surface (top panels) or basolateral surface (bottom















ere determined at the indicated times pi. The limit of detection is 1.2 log10TCID50/
ace for the presence of viral antigen (green) after basolateral inoculation with eithe
n the HAE (Fig. 4A) and 60–80% of the cells in a given HAE
ulture are of the ciliated cell type [38], we estimate that only
0–20% of all ciliated cells in each culture were infected during
noculation. Infection of HAE with rHPIV2-WT produced maxi-
um titers days 1–3 pi, which was demonstrated both by high
evels of virus detected in the apical compartment and by the pro-
ortion of cells positive for HPIV2 antigen at those time points.
he numbers of infected cells declined after day 3 and reached
0% of its peak by day 6 pi (Fig. 1C). The decline in the num-
er of infected cells correlated with a reduction in viral titer
etermined at day 6 pi. Still, significant numbers of cells stained50
) Representative photomicrographs of HAE fixed at day 6 pi and immunoprobed en
V2 or HPIV1, or after apical inoculation with HPIV1.
positive for HPIV2 through day 6 pi, and viral shedding was
detectable in the apical compartment through the final day of sam-
pling.
Although apical inoculation of HAE by rHPIV2-WT did not
result in basolateral shedding of virus, infection of HAE via the
basolateral compartment was possible and resulted in increas-
ing apical HPIV2 titers, indicating that this route of infection
was productive (Fig. 2A). Following basolateral inoculation of
HAE with rHPIV2-WT at a MOI of 5.0 TCID50/cell, virus could be
detected in the apical compartment at titers ranging from 103.2
to 105.2 TCID50/ml by day 2 pi. To confirm that HPIV2 was indeed
A. Schaap-Nutt et al. / Vaccine 28 (2010) 2788–2798 2793
Fig. 3. Infection of LLC-MK2 cells and HAE with rHPIV2-WT and rHPIV2-VAC at temperatures reflective of the upper and lower airways. (A) Comparison of replication of




































t 24-h intervals pi. The mean titer (log10) for each time point is indicated. (B) Co
HPIV2-VAC (squares). HAE cells were inoculated at the apical surface with rHPIV2
7 ◦C, as indicated. Virus titers were determined in the apical compartments at the in
er donor) ± S.E., and the limit of detection is 1.2 log10TCID50/ml.
ble to infect HAE following basolateral exposure, we repeated
his experiment at a lower MOI of rHPIV2-WT (1.0 TCID50/cell).
gain, rHPIV2-WT was observed to infect the HAE both apically
nd basolaterally as evidenced by detection of increasing virus
iters in the apical wash samples (Fig. 2A). However, as virus titers
n the basolateral compartment did not increase over the course
f infection, HPIV2 appears to be shed primarily from the apical
urface regardless of inoculation route (Fig. 2A). Additional cul-
ures were inoculated (either apically or basolaterally) in parallel
ith rHPIV1-WT for comparison with rHPIV2-WT. Upon apical
noculation with rHPIV1-WT, robust HPIV1 shedding from the api-
al surface was detected, indicating productive infection of the
AE (Fig. 2A). As was previously reported [20], virus shedding
nto the basolateral compartment was not observed. Following
asolateral inoculation with rHPIV1-WT, virus was detected at
arly time points (days 0–4 pi) in the basolateral wash samples,
ut the declining titer of virus during this period suggests that
he virus detected represents residual inoculum and is not evi-
ence of replication within the HAE. In contrast to our results
or rHPIV2-WT, rHPIV1-WT virus shedding was not detected in
he apical compartment of basolaterally infected HAE. Therefore,
HPIV1-WT infects the HAE after apical but not basolateral inocula-
ion. The observation that rHPIV2-WT infected all cultures derived
rom four different donors via the basolateral surface, in con-
rast to HPIV1, which was not able to infect any of the cultures
fter basolateral inoculation, indicated that HPIV2 was capable
f entering the HAE via apical and basolateral surfaces. En face
mmunostaining for HPIV2 and HPIV1 antigens verified that cells
f the HAE were infected via both apical and basolateral inocu-
ation with HPIV2 but not via basolateral inoculation with HPIV1
Fig. 2B).ison of single cycle growth curves in HAE inoculated with rHPIV2-WT (circles) or
or rHPIV2-VAC at a MOI of 5.0 TCID50/cell. Cultures were incubated at either 32 or
ed times pi. Virus titers shown are the means of 6 cultures from 2 donors (3 cultures
3.2. HAE reveal greater attenuation of rHPIV2-VAC growth than
LLC-MK2 cells
The level of replication of rHPIV2-VAC and rHPIV2-WT was com-
pared at 32 and 37 ◦C in LLC-MK2 cells and HAE to determine if HAE
are able to detect the attenuation phenotype of rHPIV2-VAC that is
not detected in LLC-MK2 cells. At 32 ◦C, the growth of rHPIV2-VAC
in LLC-MK2 cells resembles that of rHPIV2-WT (Fig. 3A), whereas
in HAE it is 30-fold lower than that of rHPIV2-WT (Fig. 3B). This
indicates that HAE can detect a non-ts att phenotype that is not
apparent in LLC-MK2 cells.
At 37 ◦C, the restriction of rHPIV2-VAC replication (compared
with rHPIV2-WT) was much more pronounced in HAE (>10,000-
fold) than in LLC-MK2 cells (10–100-fold) (Fig. 3A and B). The
moderate restriction of replication of rHPIV2-VAC in LLC-MK2 cells
at 37 ◦C is compatible with the presence of ts att mutations in the
vaccine virus [29]. Clearly, the greater restriction of replication
of rHPIV2-VAC in HAE at 37 ◦C indicates that HAE are the more
sensitive of the two systems for the detection of the attenuating
mutations in rHPIV2-VAC.
With regard to virus shedding from the basolateral surface fol-
lowing apical inoculation, rHPIV2-VAC behaved like rHPIV2-WT,
i.e., it was not shed at either temperature (data not shown).
3.3. Type I interferon induction during HPIV2 infection of HAEEpithelial cells lining the airways secrete cytokines and
chemokines, which contribute to inflammatory pathology as well
as to protective immune responses. It was previously demonstrated
that infection of HAE with rHPIV1-WT did not induce significant
levels of type I interferon (IFN) secretion, while infection with a
2794 A. Schaap-Nutt et al. / Vaccine 28 (2010) 2788–2798





























t a MOI of 5.0 TCID50/cell with rHPIV2-WT (at 37 ◦C) or rHPIV2-VAC (at 32 ◦C) or with
hen immunoprobed with antibodies to HPIV2 (green) and acetylated alpha tubulin
nly in ciliated columnar epithelial cells and not in mock-inoculated HAE. (B) Repr
nd eosin.
PIV1 mutant encoding a defective HPIV1 IFN antagonist C pro-
ein induced high levels of IFN [20]. In these previous studies the
nduction of IFN correlated with the restriction of replication of the
PIV1 mutant in the HAE model. In the present study, we com-
ared the concentration of type I IFN in the apical compartment
ollowing infection with rHPIV2-WT or rHPIV2-VAC to determine
hether IFN played a role in the restriction of replication of either
irus. Type I IFN was not (rHPIV2-VAC) or barely (rHPIV2-WT,
5 pg/ml IFN detected on day 4 only at 37 ◦C, lower limit of detec-
ion = 30 pg/ml) detectable in the apical compartment of cultures
aintained at either 32 or 37 ◦C during the 6 days of study. This
bservation implies that a strong inhibition of IFN induction is oper-
tive in both WT and mutant HPIV2, supporting data from cell lines
nfected by HPIV2 [39–48]. These findings indicate that the atten-
ation of rHPIV2-VAC for HAE is mediated by mutations that do
ot directly involve IFN production and that the restricted replica-
ion of rHPIV2-VAC specified by the attenuated mutations might
ontribute to the weak IFN response.
.4. HPIV2 infects ciliated cells in HAE without causing gross
orphological changesTo determine the cell types targeted by HPIV2 and to character-
ze the effects of infection on airway epithelial cell morphology,
istological cross-sections of HAE were stained for HPIV2 and
cetylated alpha-tubulin, a marker of ciliated cells. Viral antigen
as detected throughout the cytoplasm of cells that also stainedol fluid (mock). At day 6 pi, cells were fixed and prepared as histological sections and
to detect virus antigen and ciliated cells, respectively. HPIV2 antigen was detected
ative histological cross-sections of infected HAE counterstained with hematoxylin
positive for acetylated alpha-tubulin, indicating that ciliated cells
are infected by rHPIV2-WT, although not every ciliated cell was
infected even at late time points (Fig. 4A). Ciliated cells were also
infected following basolateral inoculation with HPIV2-WT (data not
shown). Similar to rHPIV2-WT, rHPIV2-VAC also targeted ciliated
cells of the HAE (Fig. 4A). Morphological assessment of histological
cross-sections revealed that infection with HPIV2 did not induce
gross changes in morphology or in the integrity of the epithelium
when compared to the mock-inoculated cultures (Fig. 4B). Sec-
tions of HAE fixed on the final day of sampling (day 6) showed
that neither rHPIV2-WT nor rHPIV2-VAC infection was associated
with overt cytotoxicity or syncytia formation. In addition, mucocil-
iary function determined by visual inspection of ciliary motion in
infected HAE using a light microscope at each time point did not
appear to be significantly compromised by HPIV2 infection. Alcian
blue-PAS staining revealed slightly increased mucin production at
72 h pi in virus-infected cultures compared with mock-inoculated
cultures (data not shown).
3.5. Cellular cytotoxicity induced by HPIV2 infection
We next evaluated whether infection with HPIV2 induced cyto-
toxicity in HAE that was undetectable by gross morphological
analysis. Cytotoxicity can be evaluated by the quantification of
plasma membrane damage resulting in the release of cytoplasmic
contents into the extracellular space, i.e., the surrounding fluid. A
ubiquitous cellular protein rapidly released into culture medium
































ig. 5. Cellular cytotoxicity induced by HPIV2 infection. Cytotoxicity was quantifi
-axis). Adenylate kinase in the sample activated a bioluminescent detection reagen
s relative luminescence units (RLU). Virus titers in the apical samples are shown a
s a result of plasma membrane damage is adenylate kinase (AK).
y measuring AK activity in the same apical wash samples used to
etermine virus titers, it was possible to correlate the amount of
rogeny virus released with the level of cytotoxicity for that par-
icular culture. For rHPIV2-WT infected HAE cultures maintained
t either 32 or 37 ◦C (Fig. 5A and C, respectively), AK release peaked
t day 4 pi, following peak levels of ongoing viral replication and
orrelating with lower virus titers at the same time point. How-
ver, infection with rHPIV2-VAC at either temperature induced
inimal AK release (Fig. 5B and D), substantially less than that asso-
iated with rHPIV2-WT infection, indicating at the very least that
ncreased virus replication correlated with increased AK release.
o significant AK release was detected in mock-infected cultures
hat were handled identically (data not shown). The relatively tran-
ient increase in AK release in the rHPIV2-WT-infected HAE was
ot associated with significant alterations in the morphology of
he epithelium in any of the cultures (Figs. 4 and 5, and data not
hown).
.6. Comparison of virus replication of rHPIV2-WT and
HPIV2-VAC vaccine candidate in African green monkeys and HAE
In order to determine whether attenuation in the HAE model
orrelated with the att phenotype of rHPIV2-VAC in AGMs, we
ompared rHPIV2-VAC and rHPIV2-WT virus titers in the apical
ashes of HAE and in the respiratory secretions of AGMs. For eitherirus, the mean virus titer in day 3 apical washes of HAE incubated
t 32 ◦C was approximately 100-fold higher than the mean peak
iter in the URT (upper respiratory tract, nasopharyngeal swab)
f AGMs (Fig. 6A), and the difference was approximately 5-fold
etween HAE at 37 ◦C and the LRT (lower respiratory tract, tra-measuring adenylate kinase activity in apical wash samples (circles, scale on left
iLight BioAssay Kit), which was detected using a luminometer; activity is expressed
ed lines for reference and use the same scale as Fig. 2A (scale on right y-axis).
cheal lavage fluid) of AGMs (Fig. 6B). The restriction of replication
of rHPIV2-VAC versus rHPIV2-WT was 1.5 log10 in the URT of AGMs
(P < 0.001) and 1.6 log10 in HAE cultures at 32 ◦C (P < 0.01) whereas
it was 3.9 log10 in the LRT of AGMs (P < 0.001) and 4.1 log10 in HAE
at 37 ◦C (P < 0.001), indicating a good correlation between the two
systems for either temperature.
4. Discussion
The focus of this study was to characterize rHPIV2-WT infection
in an in vitro model of HAE and to assess the utility of this model for
evaluating phenotypes of candidate live attenuated virus vaccines.
Although animal models have given important clues to the level
of attenuation of potential vaccine strains, we sought to establish
a human tissue culture system that reflects attenuation of respi-
ratory virus vaccine candidates in seronegative humans. Towards
this goal, we compared replication of a HPIV2 vaccine candidate
currently in clinical trials and a WT HPIV2 virus in HAE and evalu-
ated several factors that affect viral pathogenesis in the respiratory
epithelium, including cytotoxicity, target cell type, polarity of virus
release, and ability of these viruses to induce an IFN response.
The concept that HAE may be useful as a tool to correlate in
vitro attenuation with in vivo attenuation is supported by studies
in which attenuating mutations in several other respiratory viruses,
including influenza A and B viruses, RSV, HPIV1 and HPIV3, all
exhibited reduced growth in HAE compared to their parent strain
[20,49–51]. Furthermore, data from these studies demonstrated a
correlation between attenuation in HAE and attenuation in ani-
mal models and/or in seronegative children [50]. Specifically, levels
of attenuation of two HPIV1 vaccine candidates exhibiting differ-
ent levels of attenuation in AGMs was accurately reflected in HAE,
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Fig. 6. Comparison of replication of rHPIV2-WT and rHPIV2-VAC in African green
monkeys and HAE cultures. (A) Titers of rHPIV2-WT and rHPIV2-VAC in the URT
(upper respiratory tract) of AGMs and in the apical wash of HAE incubated at 32 ◦C.
(B) Virus titers in the LRT (lower respiratory tract) of AGMs and in the apical wash of
HAE incubated at 37 ◦C. In both graphs, the peak virus titer, irrespective of sampling
day, for each AGM is indicated by a circle (rHPIV2-WT infected AGMs) or square
(rHPIV2-VAC infected AGMs). Virus titers from HAE were determined in high MOI
































compared to uninfected cultures from the same donor. However,t day 3 pi. Lines indicate the mean peak titer for each group ± S.E. A single aster-
sk (*) indicates statistical significance with P value > 0.01, while (**) indicates a P
alue > 0.001 (two-way ANOVA with Bonferroni post-tests).
ndicating the potential for evaluating respiratory virus vaccine
andidates in this model [20,51]. Studies evaluating attenuation of
nvestigational RSV vaccines also found a good correlation between
heir growth in HAE with that in chimpanzees and seronegative
hildren [50].
In the current study, in a comparison with rHPIV2-WT, rHPIV2-
AC was restricted in replication in HAE to a level that closely
irrors its attenuation in vivo in AGMs. Mean peak titers of rHPIV2-
AC were 30–40-fold below rHPIV2-WT in both the URT of AGMs
nd in HAE at 32 ◦C. The restriction of rHPIV2-VAC replication in
AE at 32 ◦C was not observed in the non-polarized LLC-MK2 cell
ine, where its replication was equivalent to that of rHPIV2-WT at
ermissive temperature. Thus, rHPIV2-VAC contains a host range
ttenuating mutation that specifies attenuation (i.e., restricted
eplication) in AGMs and HAE (32 ◦C) but not in LLC-MK2 cells. We
uggest that the restriction in replication of rHPIV2-VAC at the per-
issive temperature of 32 ◦C in HAE is due to the 15T–C mutation
n the 3′ genomic promoter, which was shown previously to be a
on-ts mutation that specifies attenuation in both the URT and LRT
f AGMs [29]. In both HAE at 37 ◦C and the LRT of AGMs, rHPIV2-
AC replication was highly attenuated (approximately 10,000-fold
ower titers than rHPIV2-WT) likely due to the additive effects
f the non-ts and ts attenuating mutations [29]. The correlation
etween the extent of vaccine attenuation in HAE and AGMs further
trengthens the concept that HAE models are useful for deter-
ining the attenuation phenotypes of potential respiratory virus
accine candidates. Other recent data with a V-deletion mutant
f HPIV2, rHPIV2-Vko, also showed that attenuation of HPIV2 in
ivo may be reflected in HAE, as this mutant was unable to grow28 (2010) 2788–2798
to detectable levels in either HAE or AGMs [52]. However, clear
demonstration of a quantitative correlation between attenuation
in vivo and in HAE will require more extensive testing of a panel of
viruses with varying levels of attenuation in both systems. Once the
safety, level of replication, and immunogenicity of rHPIV2-VAC is
determined in seronegative children, the level of sensitivity of both
the AGM and HAE models in identifying a satisfactory level of atten-
uation of rHPIV2-VAC for humans will be known. If the rHPIV2-VAC
is under-attenuated for seronegative infants, viruses that are more
attenuated than rHPIV2-VAC in comparative studies in HAE and/or
AGMs will be selected for further evaluation in humans.
Our finding that the ciliated cells of HAE are permissive for
HPIV2 infection is consistent with several other respiratory viruses
including influenza A virus, SARS-CoV, RSV, HPIV1 and HPIV3
[20–23,53]. Although HPIV2 infection of HAE was less robust than
that of HPIV1 and HPIV3 [20,21], HAE clearly supported HPIV2 repli-
cation with amplification of virus titer and can therefore be used to
model characteristics of HPIV2 infection of the human respiratory
tract in vivo. The level of HPIV2 replication in HAE correlates with
that seen in human cell lines [52], and may be a reflection of the
lower incidence of severe disease associated with the virus versus
the other HPIVs [2].
The ability of rHPIV2-VAC to infect HAE at 32 ◦C and to replicate
to a peak titer of approximately 104.5 TCID50/ml suggests that this
virus will productively infect the upper respiratory tract of humans,
thereby triggering an adaptive immune response in the vaccine.
In addition to its restricted replication, we observed a decline in
virus titers from day 3 onward, indicating that, even in the absence
of immune cells and a humoral immune response, virus replica-
tion is restricted by the innate epithelial immune system. Initially,
we suspected that this decrease in virus shedding might be due
to the production of cytokines and other immune mediators by
the epithelial cells that suppress virus growth. Previous studies
with HPIV1 mutants possessing mutations that disable the viral IFN
antagonist genes indicated that type I IFN secreted by HAE cells was
capable of reducing replication of viruses that were rendered sus-
ceptible to the antiviral effects of IFN [20]. However, our evaluation
of the type I IFN response showed no link between IFN production
in HAE and the reduction of HPIV2 replication, though this does not
rule out a contribution of other innate epithelial cell responses to
limiting virus replication. This was not surprising since rHPIV2-VAC
does not posses mutations in the V protein, the known IFN antago-
nist gene of HPIV2. Rather, the failure to detect IFN in the cultures of
rHPIV2-VAC infected cells reflects the restricted replication of this
virus imposed by the mutations in L and the 3′ genomic promoter.
Future studies in HAE will likely further our understanding of both
the innate immune responses of airway epithelial cells that limit
the extent and duration of respiratory virus infection and the mech-
anisms by which host range mutations, such as the 15T–C mutation,
restrict replication in human ciliated epithelial cells.
In addition to cytokine production, in vivo infection with res-
piratory viruses can cause dramatic changes in the respiratory
epithelium. For example, influenza virus infection results in dra-
matic cytopathic effects in the columnar cells of HAE cultures
within 48 h, with early cessation of cilial beat and eventual loss of
columnar epithelial cells, although basal epithelial cells are spared
[24,26]. In contrast, cytopathology induced in HAE by HPIV1, HPIV3,
and RSV infections is much more subtle than that induced by
influenza viruses [21,22]. Similarly, infection of HAE with HPIV2
did not induce syncytia formation or disruption of overall mucocil-
iary function, and epithelial integrity was not dramatically alteredthese observations may be due partly to the low number of cells
infected in each culture as cytotoxicity assays detected some alter-
ations in the HAE that were not observed in histological analyses.
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y cytopathic effect of viral infection or by cellular apoptotic mech-
nisms. In contrast to rHPIV2-WT, rHPIV2-VAC exhibited minimal
ytotoxicity determined by AK release, corresponding to lower lev-
ls of replication.
In the polarized HAE model, the apical compartment represents
he airway lumen, while the basolateral compartment represents
he interstitial and vascular support of the lungs. Because HPIV vac-
ines are being developed for intranasal inoculation, vaccine strains
ust be able to productively infect apical, or luminal, cell surfaces
or intranasal administration. Our studies confirmed that inocula-
ion of the apical surface of HAE is a productive route of infection
or rHPIV2-VAC, which supports intranasal inoculation as a means
f vaccination. Interestingly, HPIV2 also appears to be able to enter
he HAE via the basolateral surface. Other paramyxoviruses, such as
easles virus (genus Morbillivirus), can also enter HAE via the baso-
ateral surface yet, like HPIV2, measles virus is released primarily
pically [25,54,55]. Whether the ability of HPIV2 to infect HAE after
asolateral inoculation is of biological significance is unknown as
o indication of HPIV2 viremia has been reported and signs of sys-
emic illness (other than fever) are not seen in immunocompetent
ndividuals [56].
Significantly, following inoculation with rHPIV2-WT or rHPIV2-
AC, virus shedding appears to be primarily at the apical side of
he polarized HAE cultures. In vivo, this would result in shedding
nto the lumen and away from underlying tissues, increasing the
ikelihood that infection will remain localized to epithelial sur-
aces in the respiratory tract. Although apical budding is not the
nly mechanism that restricts systemic spread of a virus, a similar
estriction of virus release to apical surfaces has also been seen pre-
iously with the related parainfluenza viruses HPIV1 and HPIV3,
s well as RSV and influenza A virus, and is consistent with the
attern of infection limited to the respiratory tract that is typically
een throughout the course of disease during human infection with
PIV2 [20–22,24]. Clinical data also indicate that WT HPIV2 is shed
umenally and present in respiratory secretions whereas viremia
r replication at distant sites has not been reported [57]. Similarly,
PIV2 viremia was not detectable in spite of high titer replication
n the URT and LRT of AGM (unpublished data, ASN, ACS, and BRM).
he observation that rHPIV2-VAC is released from the apical sur-
ace is important for vaccine development because it will unlikely
ause viremia or spread to systemic organs in vaccines.
In summary, the rHPIV2-VAC investigational vaccine has been
haracterized extensively in HAE and in AGMs and was highly
ttenuated in both. This study extended analysis of rHPIV2-VAC to a
uman in vitro model system that is likely predictive of HPIV repli-
ation in the airways of seronegative children and demonstrated
consistent, high level of attenuation for rHPIV2-VAC in human
iliated epithelial cells at 37 ◦C, indicating that it is very unlikely
o cause severe lower respiratory disease in seronegative children.
he close correlation between limited growth of rHPIV2-VAC ver-
us that of rHPIV2-WT in both AGMs and in HAE provides additional
vidence that this virus will be attenuated in humans. Since rHPIV2-
AC is currently being evaluated in clinical trials as a live attenuated
accine candidate for HPIV2, it will be valuable to compare data
enerated in HAE models to levels of replication in seronegative
umans in order to fully assess the correlation between the level of
ttenuation of a vaccine candidate in the HAE model versus that in
umans. If the clinical trials indicate that additional HPIV2 vaccine
andidates need to be developed, HAE and rHPIV2-VAC can be used
ogether to assess which candidates have favorable attenuation
rofiles for clinical development.cknowledgements
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